INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM

Core Viewpoint - Pomerantz LLP is investigating claims on behalf of investors of Insmed Incorporated regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1]. Group 1: Company Performance - On December 17, 2025, Insmed announced that the Phase 2b BiRCh study of brensocatib in patients with chronic rhinosinusitis without nasal polyps did not meet its primary or secondary efficacy endpoints in both the 10 mg and 40 mg treatment arms [3]. - Following the announcement of the trial results, Insmed's stock price dropped by $31.91 per share, representing a decline of 16.08%, closing at $166.55 per share on December 18, 2025 [3]. Group 2: Legal Investigation - Pomerantz LLP, a firm recognized for its expertise in corporate, securities, and antitrust class litigation, is leading the investigation into Insmed's potential misconduct [4]. - The firm has a history of recovering significant damages for victims of securities fraud and corporate misconduct, indicating a strong focus on protecting investor rights [4].